Amgen Inc., a biotechnology company specializing in the discovery, development, manufacturing, and marketing of drugs for serious illnesses, continues to maintain a significant presence in the healthcare sector. The company focuses on human therapeutics, utilizing cellular and molecular biology to develop novel medicines.

As of the market close on November 15, 2026, Amgen Inc. was trading at 462.32 USD on the Nasdaq exchange. The company’s market capitalization is valued at 251,890,000,000 USD, with a price-to-earnings ratio of 27.05.

In terms of recent stock performance, the company reached a 52-week high of 483.99 USD on November 4, 2026. Over the past year, the stock has fluctuated between a 52-week low of 312.39 USD, recorded on December 10, 2025, and its recent high.